►
From YouTube: Open Source Antibiotics Science Update Nov 13 2020
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/40
On the call: Professor Matthew Todd, Dr Dana Klug, Dr Edwin Tse, Giada Sabatino (UCL) Dr Chris Swain (Cambridge MedChem Consulting), Anthony Sama, Lori Ferrins (Northeastern).
A
All
right,
hi,
everybody
welcome
to
the
open
source,
antibiotics,
friday,
the
13th
november,
and
so
thanks
for
coming
along
and
let
me
share
my
screen
so
that
we're
all
looking
at
the
same
thing.
A
So
this
is
the
issue
I
just
started
on
github
and
the
I
sorry
for
the
delay.
A
I
put
the
recording
up
for
the
meeting
last
time
just
just
this
morning,
and
I
I
edited
a
little
bit
of
the
text
here
which
I'll
copy
over
to
the
new
issue
for
today
about
some
decisions
we
made
on
compound
design
last
time
mainly
around
modification
of
the
power
position
of
that
active
compound,
and
I
guess
we
can
re-engage
with
some
of
that
when
we
do
the
chemistry
slide
in
a
minute,
so
for
just
on
the
the
screening
side
laurie
you
you
sent
in
some
structures
of
some
compounds
there.
A
That
looks
really
interesting
that
you
were
happy
to
to
share
now
from
I
mean
so
from
my
naive,
quick
view
here.
These
look
great,
I
mean
we.
These
are.
These
are
compounds
with
a
kind
of
pendant
amine,
which
is
alkylated,
which
is
a
I
mean.
The
dependent
amy
was
something
we
wanted
to
investigate
anyway
right,
so
these
look
amazing.
B
Yeah,
I
double
checked
some
of
them.
We
don't
know
very
much,
so
it's
going
to
be
a
case
of
scrape
out
the
glass
to
get
the
compound,
but
I
think
we
should
be
able
to
get
enough
to
send
to
you,
so
I
can
ship
all
of
these
five.
We
also
have
so
this
is
actually
an
active
part
of
what
we're
working
on
at
the
moment.
B
So
if
any
of
these
are
actually
active
or
interesting,
we
can
just
make
sure
that
we
have
enough
moving
forward
in
terms
of
so
that
we
can
actually
add
into
your
pipeline
and
go
forward
so.
B
The
these
are
active
against.
We
have.
We
have
data
points
against
t
crazy
against
ellen
phantom
as
well.
We
also
have
mrc5
and
pmm
data
in
terms
of
host
cells,
and
we
will
also
have
add
me
data
on
these
as
well,
so
I
can
share
all
of
that
with
you.
That's
amazing.
A
Fantastic
yeah
really
interesting
and
you
are
so
you're
still
actively
exploring
this
core.
B
Yes
and
we're
also
looking
at
sort
of
derivations
of
the
core
as
well,
so
I
mean
you
can
see
with
6729
at
the
bottom
that
we've
we've
got
the
substitution
substitution
even
there
we're
changing
that
up
as
well.
I
noted
somewhere
that
you
said
so,
the
the
seven
substitution
versus
the
six,
so
the
six
is
what's
on
six,
seven:
nine,
that's
just
something
that
we've
observed
in
pmm
and
mrc5
that
that
actually
tends
to
give
us
a
better
selectivity
profile.
B
How
that
actually
translates
in
vivo.
I
don't
know,
but
where
we're
pursuing
more
of
that
position
than
the
seven.
A
B
So
well,
like
I
said
so,
we've
got
pmm
and
mrc5s
for
some
of
these
we
may
have
hep
g2,
but
I
couldn't
probably
not
for
these
exact
compounds,
but
I
could
go
back
and
troll
through
the
database
and
see
if
there
is
any
other
representative
compounds
with
this
core
scaffold
that
have
other
cell
line
data
as
well.
A
Okay,
but
I
mean
so
far,
I
mean
it
looks
like
you
have
you're
exploring
this
again.
I
don't
know
if
you
say
anything,
you
don't
want
to
say,
but
you
you.
A
Okay,
because
the
if
you're
exploring
this
core,
then
as
it
stands
and
you're
making
more
of
these
things,
then
you're
keeping
this
by
dentate
motif
of
the
imidazo
pyridine
yeah.
Okay,
great!
Well,
that's
a
good
sign.
I
guess
our
main
concern
is
we're
waiting
on
top
state
of
around
but
yeah.
That's
what
we're
concerned
about.
A
Okay,
yeah.
That
would
be
great.
I
mean
I
forget
sorry
dana.
I
forget
how
much
we
typically
needed
for
paul's
mrsa
essay.
A
Okay,
awesome,
that's
wonderful,
okay!
So
yes,
I
mean
the
answer
is
yes,
we
would
love
to
have
samples
if
you
are
happy
to
donate
them,
I
mean,
I
guess
you
know
it
works
both
ways
too
right.
So
I
mean,
if
you
see
things
that
we're
making
that
you
would
like.
Then
you
know
it's
reciprocal.
A
Very
good,
so
there
were
some
other
points
about
compound
design
as
well,
which
I'll
summarize
from
last
time
which
I'll
summarize.
But
I
don't
think
it's
changed
in
the
last
week
or
so,
but
I'll
copy
those
over
from
last
time
to
the
minutes
of
this
meeting
and
then
just
the
update
on
the
cytotalk.
So
I
guess
those
things
are
being
measured
in
andreas's
lab.
Is
that
right
and
we're
going
to
be
waiting
a
couple
weeks?
Maybe.
A
Okay,
so
nothing
much
to
be
done
then,
and
we'll
have
to
take
it
from
there
all
right
when
we
can
maybe
have
a
look
at
chemistry,
which
is
any
chemistry
which
has
happened
this
week.
E
E
I
tried
to
do
this
bottom
reaction,
but
I'm
not
entirely
sure
if
I've
got
the
product
there's
it's
not
gone
to
completion
but
there's
new
spots,
so
I
just
need
to
figure
out
what
there
is
in
there
and
then.
The
other
thing
is
the
compound
suggestions
from
last
week.
So.
E
I
think
yeah,
so
here
just
these
like
top
row,
ones
on
the
left
and
the
methyl
isomers.
So
those
are
the
easiest
ones.
So,
yeah
I've
bought
these
five
bronic
acids.
So
just
those
couplings
which
we
can
do
next
week.
A
A
Great,
I
think
I
used
your
lab
book
as
a
example
and
a
talk
I
gave
yesterday
where
I
was
interested
in
whether
or
not
your
lab
was
being
how
it
was
being
indexed
by
google
and
it
is
being
indexed
so
google's
finding
these
molecules,
which
is
good.
I
think,
because
I
searched
on
the
strings
and
you're
putting
those
in
yeah,
which
is
really
good,
but
it's
interesting
that
it
picks
up
the
the
entry
keys
that
you've
got
in
your
lab
notebook.
A
You
can
find
those
via
google
you,
you
come
a
little
way
down
page
one.
It
feels
like
you
should
be
at
the
top,
because
you've
actually
made
the
molecule
it
feels
like
you
should
have
a
promotion
because
of
that,
but
you
can
you're
there.
But,
interestingly,
google
is
not
searching
our
osa
molecules
spreadsheet.
F
A
Weird,
I
thought
it
was
public
yeah
I
mean
I'm
clicking
and
I'm
not
getting
it.
I'm
assuming
it's
public,
because.
A
All
right
great,
I
mean
check
yeah
that
is
visible
because
it
should
be
visible.
Yeah.
It's
on
the
wiki.
I
think
dana
installed
it
as
on
the
list
of
resources,
sources
of
data
or
something.
F
A
Okay,
okay,
it
reminded
me,
though,
either
ed
or
dana,
on
your
lab
archives
pages.
A
Can
we
have
another
go
at
using
their
chemical
sketch
tool
because
they
are
adamant
that
it
works
that
if
you
draw
the
thing
and
then
you
click
put
it
on
the
page,
it
puts
the
metadata
in
so
maybe
a
trial
page
where
you
add
in
a
molecule
one
of
the
ones
you're
using
already
and
then
give
it
a
few
days
and
then
and
then
try
the
google
search
again,
because
it
would
be
very
useful
if
that
worked.
A
That
would
be
a
good
check
to
do
thanks
all
right,
good,
all
right
great.
So
the
oh
wait
a
minute
something
to
share
sorry.
We
can
quickly
run
through
the
remaining
things,
so
the
the
remaining
things
the
in
vitro
pk,
it's
it's
I
checked.
Yesterday
the
contract
is
still
just
sitting
there
waiting
to
be
approved,
and
I
can't
say
anything
else
about
that
publicly,
even
though
I
want
to
there
is
still
this
residual
uncertainty
about
the
units
in
the
original.
A
So
we
were
going
to
go
back
to
the
original
data
rate
and
check
what
the
units
were
and
we
were
going
to
resolve
this
issue.
I'm
pretty
sure
there's
no
issue,
but
we
need
to
resolve
this
and
get
it
off
of
our
shared
deal.
If,
if
we
could
just
take
this
action
on
me,
but
if
we
just
go
back
to
the
original
data
and
check
the
units
and
then
just
verify
that
we
don't
have
an
issue,
sorry,
that's
still
on
me.
A
D
I
just
sent
it
to
you
and
ed
in
case
you
can
send
me
feedback
before
I
make
it
public
yeah
it's
about
a
minute,
long
yeah
hard
to
get
mostly
important
points
in
there,
but.
A
Yeah,
so
my
my
my
view
of
this
is
the
eventually
what
we
do
is
we
spend
30
seconds
talking
about
one
very
specific
thing
and
you
give
a
very
nice
overview
of
things
at
the
moment,
which
is
absolutely
fine,
so
I
reckon
you
should
just
go
for
that
and
put
it
out
there
as
a
really
good
starting
point.
The
one
thing
I
didn't
see
was
the
captioning.
D
A
Okay,
awesome
and
then
see
if
it
I
don't
know
so,
then
it
would
be
really
nice
to
embed
it
somewhere
if
possible.
I
don't
know
how
you
do
that
if
you
can
share
it
and
put
it
somewhere
where
you
know
social
media.
D
Yes,
I
think,
when
I
looked
into
that
when
ta
was
doing
hers-
and
essentially
I
can
embed
it,
but
then
it
won't
have
captions
or
I
can
link
it
to
youtube
with
captions,
okay,
okay,
it's
an
issue
with
the
caption
file
type
that
I
could.
I
was
having
trouble
converting
it.
A
I
mean
first,
if
you,
if
you're
able
to
put
the
captions
on
there,
then
just
you
know
tweet
out
the
link
or
something
and
we'll
get
it
out
there,
and
then
we
can
see
how
it
looks
when
it's
embedded
somewhere.
Okay,
that's
cool.
D
I
I
just
had
I
made
like
one
slide,
so
I
saved
that
as
a
jpeg,
which
I
can
then
put
in
a
tweet
with
the
link.
Okay,
great.
A
We're
really
good
yeah,
okay
cool,
looks
great
the
newsletter.
I
want
to
send
out
another
one
pretty
soon
about
the
other
project
that
we're
doing
on
the
the
the
open
source
anabolic
series.
One
murligates
I'd
like
to
send
something
out
about
that
soon,
and
this
idea
of
having
people
sign
up
for
these
newsletters
is
an
important
one.
I
haven't
had
a
chance
to
do
that.
Does
anyone
want
to
volunteer
to
make
a
sign
up,
for
I
can
do
it,
but
I
just
I'm
I'm
having
difficulty.
D
Sure,
like
just
a
google.
D
A
A
Easy
great
thank
you.
Yeah
molecular
contributions.
We,
I
guess
we
haven't
done
that,
but
you've
got
a
submission
template.
Sorry,
I
haven't
got
that
open,
so
this
was
being
discussed.
D
Issue
for
that
with
the
template,
which
is
an
excel
sheet,
and
then
we
also
talked
about
like
just
a
an
agreement
in
terms
of
ownership,
which
I
guess
we
could
also
put
here
and
then
just
direct
people
to
this
one
page.
If
they
want
to
submit.
F
A
Yes,
so
I
think
that
we
should
be
able
to
take
that
directly
from
them
I'll
I'll
contact,
another
guy
who
wrote
that,
and
so
I
think
we
can
take
it
from
them
and
use
it
for,
for
our
case,
sorry,
that's
still
on
me
to
do,
but
that's
really
that's
really
good.
So
the
donation
spreadsheet
has
everything
we
need,
and
it's
meant
to
make
it
easier
for
people
to
send
things
in
right.
A
D
Yeah
he
said,
I
think
they
submitted
it
for
mass
spec
analysis.
I
think
he
said
two
weeks
ago.
D
So
hopefully
I
think
he
did
mention
previously
that
that
is
the
part
of
the
pipeline
that
was
backlogged,
but
then
once
they
do
that,
I
assume
that
they
do
a
little
bit
of
analysis
on
it
and
then
we
get
the
results.
A
Yeah,
okay,
all
right
good,
so
I
think
the
other
things
are
just
you
know
waiting.
I
think
that
was.
I
think
that
was
everything
right
have.
I
have
I
missed
out
anything
obvious
here.
A
I
think
chemistry's
happening
mechanism
action
stuff
is
happening.
Laurie's
very
kindly
sending
in
some
samples
box
is
happening,
so
I
think
we're
all
good.
A
Unless
there's
anything
else
that
was
outstanding,
I
mean
the
one,
the
one
thing
about
other
sources
of
compounds,
so
the
crowdsourcing
of
physical
compounds,
the
it
suddenly
occurred
to
me
the
other
day.
A
Actually
yesterday,
when
I
was
doing
this
talk
for
the
rsc
meeting
that
we
don't
have
a
systematic,
you
know
good
systematic
way
of
doing
this,
about
alerting
people
to
compounds
that
we
might
need,
but
there
is
still
some
value
in
occasionally
sending
out
structures
on
linkedin
and
and
twitter
and
stuff,
sending
out
some
simple
pictures
of
chemical
structures
that
we're
interested
in
in
case
that
catches
the
eye
of
a
chemist.
A
A
Every
now
and
again
in
the
talk
yesterday,
I
was
talking
about
the
idea
of
a
of
a
bot
that
would,
you
know,
send
out
a
tweet
with
a
structure
in
it
and
a
link
to
where
it
was
needed,
along
with
its
strings,
actually
probably
quite
easy
to
write
for
someone,
because
it
simply
takes
a
line
of
a
of
a
spreadsheet
and
then
constructs
a
tweet
out
of
it.
A
I
don't
think
that's
very
difficult,
but
we
we
can
also
see
if
we
can
write
to
you,
know,
contacts
we
have
in
in
companies
and
so
on.
Chris,
I
don't
know
what
your
senses
of
that
about
the
best
way
of
trying
to
get
through
to
people
who
may
have
related
compounds.
F
I
think
if
you
have
personal
context,
it's
probably
the
best
way
of
doing
it
and
I'm
happy
to
do
that
for
all
the
people.
I
work
with.
F
A
Yes,
you
mean
the
yes,
yes,
I
know
what
you
mean.
There's
some
emails.
I
think
that
they
yeah
you've
been
posting.
Some
things
about
meetings
there
right.
F
Yeah
yeah,
so
I
have
no
idea
how
many
people
are
involved
in
that,
but
it's
certainly
one
way
of
reaching
people
around
the
world
and
the.
I
guess,
one
of
the
things
that
we
would
like
to
do
from
the
open
chemical
sciences.
Meeting
that
we
had
is
to
have.
You
know,
think
about
how
we
could
perhaps
build
some
kind
of
network
out
of
that
as
well.
A
F
D
A
Right
right,
yep,
okay,
there
is
the
other
thing
that
we've
never
really
gone
for
is
checking
every
now
and
again.
That
compounds
of
this
kind
aren't
also
available
that
some
competitors
might
want
aren't
available
inexpensively
through
commercial
suppliers.
A
We
did
that
once
for
way
back
in
the
day
for
open
source
malaria
with
a
an
enamine
search.
This
is
now
quite
common.
Back
in
the
day
we
we
did.
We
did
a
search
for
you,
know,
enemy,
molecules
and
asked
if
they
could
give
us
free
a
bunch
of
molecules
that
were
most
similar
to
the
ones
we
were
working
on
and
they
obviously
thought
that
was
very
funny
and
laughed
us
away
from
their
doors,
but
we
did
eventually
buy
the
10
most
relevant
compounds
from
them
and
the
price
was
actually
quite
reasonable.
A
So
I
guess
we
should
always
bear
this
in
mind,
and
now
that
there
are,
you
know,
a
couple
of
search
things
that
are
coming
up
through
manifold
and
through.
I
think,
mkill
just
released
something
the
other
day
which
allows
you
to
search
for.
You
know
essentially
picture
molecule
and
ask
for
quotes
so
for
some
simple
things
we
might
hit
something.
A
I
think
some
of
the
scaffolds
we're
looking
at
are
not
trivial,
but
but
there
may
be
some
things
that
could
be
made,
which
look
quite
similar,
which
we
might
want
to
think
about
buying,
rather
than
investing
in
in
some
of
the
synthesis,
if
it's
simple,
so
a
search
every
now
and
again,
or
some
of
these
platforms
will
be
pretty
nice
to
do
just
to
keep
an
eye
on
what's
available.
F
A
G
A
Yeah,
okay,
good
was
there
anything
else
anyone
wanted
to
raise?